Several reasons may explain the observation that the mean treatment difference was 12.5% in STEP 1 and 8.7% in SELECT
Originally developed to manage type 2 diabetes, Semaglutide has been shown to significantly reduce body weight by working on the brains appetite-regulating centers
is contracted via the University of Liverpool (no personal payment) to undertake consultancy for Altimmune, AstraZeneca, Boehringer Ingelheim, Cytoki, Eli Lilly, Napp, Novo Nordisk, Menarini, Pfizer, Rhythm Pharmaceuticals, Sanofi, Saniona, Tern Pharmaceuticals, Shionogi and Ysopia
for the BPC-157 deep dive, see What Is BPC-157
It addresses why metabolism slows, not just how to force fat loss despite a struggling metabolism